TACE Combined With Penpulimab and Anlotinib for Advanced HCC

• Status: Not yet recruiting
• Trial end date: 2024-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the optimum interval of the combination of penpulimab and anlotinib with TACE in advanced HCC patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongda Hospital

Criteria

Inclusion criteria: (1) Pathologically or clinically diagnosed HCC patients; (2) Age of 18-80; (3) Barcelona Clinic Liver Cancer (BCLC) stage C (ie, China Liver Cancer Staging (CNLC) stage III); (4) with expect survival ≥ 3 months; (4) with obtained informed consent; (5) will receive penpulimab and anlotinib combined with or without TACE.

Exclusion criteria: (1) Contraindications of penpulimab and anlotinib; (2) Child-Pugh C; (3) Key information (such as imaging, liver function, Eastern Cooperative Oncology Group(ECOG) score, etc.) missing.